Brief: Neurotrope To Evaluate Potential Opportunities For Lead Therapeutic Candidate Bryostatin
08/10/2019 13:37
Oct 8 (Reuters) - Neurotrope Inc NTRP.O :
* NEUROTROPE ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES TO
MAXIMIZE SHAREHOLDER VALUE
* NEUROTROPE INC - TO EVALUATE POTENTIAL OPPORTUNITIES FOR
LEAD
THERAPEUTIC CANDIDATE BRYOSTATIN
* NEUROTROPE INC - CONTINUING TO DETERMINE HOW TO PROCEED
WITH
RESPECT TO COMPANY'S CURRENT DEVELOPMENT PROGRAMS FOR
BRYOSTATIN-1
Source text for Eikon: ID:nPn7MYgyqa
Further company coverage: NTRP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NextTrip
See all newsBrief: Nexttrip - Announces Joint Venture With Ttand In Canada - SEC Filing
Nexttrip Inc reports results for the quarter ended August 31 - Earnings Summary
Nexttrip Inc expected to post a loss of 14 cents a share - Earnings Preview
Nexttrip Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: NextTrip Enters At-The-Market Offering Agreement With Titan Partners Securities On August 31